Maintenance Osimertinib Demonstrates PFS Benefit in Stage II

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

Related Keywords

United States , Japan , Georgia , Atlanta , America , Suresh Ramalingam , Susan Galbraith , Astrazeneca , Winship Cancer Institute Of Emory University , World Health Organization , Oncology Research Development At Astrazeneca , Winship Cancer Institute , Emory University , South America , Oncology Research , D , Osimertinib , Nsclc , Egfr Mutant Nsclc , Phase 3 Laura Trial Nct03521154 ,